Becton Dickinson (BDX) and Ypsomed are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe. This is designed to be fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform, expanding options for pharmaceutical companies and patients who require large-volume subcutaneous self-injections.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up
- BD’s BD Prevue II Study Wraps Up: What a Post‑Market Win Could Mean for BDX Investors
- BDX’s SiteRite 9 Study Completion: What Investors Should Know About This Post‑Market Milestone
- Becton Dickinson receives FDA clearance for EnCor EnCompass
- Becton Dickinson to invest $110M to expand prefillable syringe production